MID3: Mission Impossible or Model-Informed Drug Discovery and Development? Point-Counterpoint Discussions on Key Challenges.

Clicks: 404
ID: 84447
2020
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #5 of 11 articles by views in clinical pharmacology and therapeutics

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
MID3: Mission Impossible, or Model-Informed, Drug Discovery and Development? At the 2019 ASCPT annual meeting, point-counterpoint discussions were held on key challenges that limit, and future directions that enhance the adoption of MID3 across the drug discovery, development, regulatory and utilization continuum. We envision that the opportunities discussed, and lessons learned from having contrasting perspectives on issues that lack consensus may aid our discipline in more effectively implementing MID3 principles.
Reference Key
krishnaswami2020mid3clinical Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Krishnaswami, Sriram;Austin, Daren;Della Pasqua, Oscar;Gastonguay, Marc R;Gobburu, Jogarao;van der Graaf, Piet H;Ouellet, Daniele;Tannenbaum, Stacey;Visser, Sandra A G;
Journal clinical pharmacology and therapeutics
Year 2020
DOI
10.1002/cpt.1788
URL
Keywords
statistics pharmacometrics model-informed drug discovery and development modeling and simulation quantitative pharmacology

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.